Glaxosmithkline | GSK - Operating Expenses


Glaxosmithkline reported GBP5.34B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
Bausch Health Companies USD 1.95B 128M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 10.2B 912M Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Perrigo USD 290.5M 645.1M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 213.19M 7.06M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Zoetis USD 3.15B 85M Jun/2026